Filtered By:
Drug: Zocor

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 44 results found since Jan 2013.

Simvastatin prevents neuroinflammation by inhibiting N‐methyl‐D‐aspartic acid receptor 1 in 6‐hydroxydopamine‐treated PC12 cells
This study investigates the impact of simvastatin on neuroinflammation in experimental parkinsonian cell models. 6‐Hydroxydopamine (6‐OHDA)‐treated pheochromocytoma‐12 (PC12) cells were used to investigate the neuroprotective nature of simvastatin. After incubation with 6‐OHDA, simvastatin, and/or N‐methyl‐D‐aspartic acid receptor 1 (NMDAR1) siRNA for 24 hr, test kits were used to detect the levels of lactate dehydrogenase (LDH) and glutamate released from PC12 cells exposed to different culture media. The mRNA levels of tumor necrosis factor (TNF)‐α, interleukin (IL)−1β, and IL‐6 were determined by...
Source: Journal of Neuroscience Research - January 31, 2014 Category: Neuroscience Authors: Junqiang Yan, Jiachun Sun, Lina Huang, Qizhi Fu, Ganqin Du Tags: Research Article Source Type: research

Simvastatin  treatment promotes proliferation of human dental pulp stem cells via modulating PI3K/AKT/miR-9/KLF5 signalling pathway
J Cell Mol Med. 2021 Nov 19. doi: 10.1111/jcmm.16973. Online ahead of print.ABSTRACTSimvastatin serves as an effective therapeutic potential in the treatment of dental disease via alternating proliferation of dental pulp stem cells. First, western-blot and real-time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR-9 and KLF5, or determine the effect of miR-9. Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin...
Source: J Cell Mol Med - November 20, 2021 Category: Molecular Biology Authors: Jing-Hui Wang Dang-En He Source Type: research

Estrogen receptor mediates simvastatin-stimulated osteogenic effects in bone marrow mesenchymal stem cells.
In this study, we hypothesize that the estrogen receptor (ER) mediates simvastatin-induced osteogenic differentiation. ER antagonists and siRNA were used to determine the involvement of the ER in simvastatin-induced osteogenesis in mouse bone marrow mesenchymal stem cells (D1 cells). Osteogenesis was evaluated by mRNA expression, protein level/activity of osteogenic markers, and mineralization. The estrogen response element (ERE) promoter activity and the ER-simvastatin binding affinity were examined. Our results showed that the simvastatin-induced osteogenic effects were decreased by treatment with ERα antagonists and ER...
Source: Biochemical Pharmacology - September 24, 2015 Category: Drugs & Pharmacology Authors: Chuang SC, Chen CH, Fu YC, Tai IC, Li CJ, Chang LF, Ho ML, Chang JK Tags: Biochem Pharmacol Source Type: research

Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
CONCLUSIONS: MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment. PMID: 31178149 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC Tags: Gynecol Oncol Source Type: research

Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
This study investigated overcoming resistance to EGFR-TKI using simvastatin. We demonstrated that addition of simvastatin to gefitinib enhanced caspase-dependent apoptosis in T790M mutant NSCLC cells. Simvastatin also strongly inhibited AKT activation, leading to suppression of β-catenin activity and the expression of its targets, survivin and cyclin D1. Both insulin treatment and AKT overexpression markedly increased p-β-catenin and survivin levels, even in the presence of gefitinib and simvastatin. However, inhibition of AKT by siRNA or LY294002 treatment decreased p-β-catenin and survivin levels. To determine the rol...
Source: Experimental Cell Research - March 12, 2014 Category: Cytology Authors: Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR Tags: Exp Cell Res Source Type: research

Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through ...
Conclusion Combined treatment with sulindac and simvastatin augmented their apoptotic potential in lung cancer cells through AKT signaling-dependent downregulation of survivin. These results indicate that sulindac and simvastatin may be clinically promising therapies for the prevention of lung cancer.
Source: Cancer Research and Treatment - October 26, 2014 Category: Cancer & Oncology Tags: Original Article Source Type: research

Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis*
Conclusions: 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors may operate through a novel Foxo1-angiopoietin-2 mechanism to suppress de novo production of angiopoietin-2 and thereby ameliorate manifestations of sepsis. Given angiopoietin-2’s dual role as a biomarker and candidate disease mediator, early serum angiopoietin-2 measurement may serve as a stratification tool for future trials of drugs targeting vascular leakage.
Source: Critical Care Medicine - June 17, 2015 Category: Emergency Medicine Tags: Online Laboratory Investigations Source Type: research

The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells.
CONCLUSIONS: Simvastatin restored the expression of BIM to induce apoptotic cell death in NSCLC cells harboring an EGFR-resistant mutation. Our study suggests the potential utility of simvastatin as a BIM-targeted treatment for NSCLC. PMID: 26756263 [PubMed - in process]
Source: Experimental Lung Research - February 18, 2016 Category: Respiratory Medicine Tags: Exp Lung Res Source Type: research

The anti ‑dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression.
The anti‑dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression. Mol Med Rep. 2016 Jul 13; Authors: Bryan-Marrugo OL, Arellanos-Soto D, Rojas-Martinez A, Barrera-Saldaña H, Ramos-Jimenez J, Vidaltamayo R, Rivas-Estilla AM Abstract Dengue virus (DENV) susceptibility to cholesterol depleting treatments has been previously reported. There are numerous questions regarding how DENV seizes cellular machinery and cholesterol to improve viral production and the effect of cholesterol sequestering agents on the cellular antiviral response. The aim of...
Source: Molecular Medicine Reports - July 21, 2016 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Simvastatin Up ‐Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen‐Independent Human Prostate Cancer Cells
CONCLUSIONOur results suggest that statins inhibit the proliferation, migration, and invasion of androgen‐independent prostate cancer cells by up‐regulation of ANXA10. Additionally, it is possible that S100A4 plays a role in these effects. Statins may be beneficial in the prevention and/or treatment of prostate cancer. Prostate © 2016 Wiley Periodicals, Inc.
Source: The Prostate - November 7, 2016 Category: Urology & Nephrology Authors: Yoshiyuki Miyazawa, Yoshitaka Sekine, Haruo Kato, Yosuke Furuya, Hidekazu Koike, Kazuhiro Suzuki Tags: Original Article Source Type: research